| pubmed-article:11325797 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0069676 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C1135918 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0003483 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0360714 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0666497 | lld:lifeskim |
| pubmed-article:11325797 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:11325797 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11325797 | pubmed:dateCreated | 2001-4-30 | lld:pubmed |
| pubmed-article:11325797 | pubmed:abstractText | 1. It has been suggested that osteopontin promotes the development of atherosclerosis, especially under diabetic conditions. 2. In the present study, we found that NK-104, a new potent synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, reduced osteopontin expression both at protein and mRNA levels in cultured rat aortic smooth muscle cells. 3. The inhibitory effect of NK-104 was almost completely reversed by mevalonate, suggesting that mevalonate or its metabolites play important roles in the regulation of osteopontin expression. 4. Furthermore, oral administration of NK-104 (3 mg kg(-1) day(-1) for 7 days) effectively suppressed abnormally upregulated expression of osteopontin mRNA in the aorta and kidney of streptozotocin-induced diabetic rats. 5. These data support a notion that NK-104 is a suitable drug for the treatment of diabetic patients with hypercholesterolaemia. | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11325797 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325797 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11325797 | pubmed:month | May | lld:pubmed |
| pubmed-article:11325797 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:SaitoYY | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:TakemotoMM | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:MoriSS | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:KitaharaMM | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:TakiMM | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:YokoteKK | lld:pubmed |
| pubmed-article:11325797 | pubmed:author | pubmed-author:AsaumiSS | lld:pubmed |
| pubmed-article:11325797 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11325797 | pubmed:volume | 133 | lld:pubmed |
| pubmed-article:11325797 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11325797 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11325797 | pubmed:pagination | 83-8 | lld:pubmed |
| pubmed-article:11325797 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:meshHeading | pubmed-meshheading:11325797... | lld:pubmed |
| pubmed-article:11325797 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11325797 | pubmed:articleTitle | NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. | lld:pubmed |
| pubmed-article:11325797 | pubmed:affiliation | Second Department of Internal Medicine, School of Medicine, Chiba University, 1-8-1 Inohana, Chiba 260-0856, Japan. | lld:pubmed |
| pubmed-article:11325797 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11325797 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325797 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325797 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325797 | lld:pubmed |
